Clinical case of locally advanced renal cell carcinoma with an inferior vena cava tumor thrombus treated with VEGFR-TKI/IO combination pembrolizumab + lenvatinib
Open Access
- 9 May 2025
- journal article
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (1) , 92-99
Abstract
The article presents a clinical case of treatment of a young man with locally advanced renal cell carcinoma with an inferior vena cava tumor thrombus above the diaphragm. Due to non-standard neoadjuvant approach of using modern tyrosine kinase inhibitors of VEGFR and immunotherapy (VEGFR-TKI/IO) combination pembrolizumab + lenvatinib, thoracotomy was avoided and complete pathological regression of the tumor was achieved. Various studies on neoadjuvant therapy of kidney cancer including in patients with tumor thrombus are discussed, and the prospects for introducing this approach into clinical practice are described.Keywords
This publication has 11 references indexed in Scilit:
- Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future DirectionsEuropean Urology Oncology, 2024
- Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trialJournal for ImmunoTherapy of Cancer, 2024
- A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).Journal of Clinical Oncology, 2024
- Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinomaNature Communications, 2023
- Current Approaches in Surgical and Immunotherapy-Based Management of Renal Cell Carcinoma with Tumor ThrombusBiomedicines, 2023
- Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell CarcinomaJACC: Cardiooncology, 2022
- Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).Journal of Clinical Oncology, 2022
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaNew England Journal of Medicine, 2021
- Renal Cell Carcinoma with Inferior Vena Cava Extension: Can Classification Be Optimized to Predict Perioperative Outcomes?Kidney Cancer, 2020
- Natural history of untreated renal cell carcinoma with venous tumor thrombusUrologic Oncology: Seminars and Original Investigations, 2013